Abstract / Description of output
In the OASIS-5 trial, fondaparinux reduced major bleeding with similar short-term efficacy as enoxaparin but lowered death and stroke during long-term follow-up. The mechanism of lower bleeding and improved efficacy with fondaparinux is uncertain.
Original language | English |
---|---|
Pages (from-to) | 243-9 |
Number of pages | 7 |
Journal | Journal of Thrombosis and Haemostasis |
Volume | 8 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2010 |
Keywords / Materials (for Non-textual outputs)
- anticoagulants
- hemorrhage
- heparin
- myocardial infarction